Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review

Background The NIA-AA research framework proposes a purely biological definition of Alzheimer’s disease (AD). This implies that AD can be diagnosed based on biomarker abnormalities, irrespective of clinical manifestation. While this brings opportunities, it also raises challenges. We aimed to provide an overview of considerations regarding the disclosure of AD pathology before the onset of dementia. Methods A systematic literature review was conducted and reported according to PRISMA guidelines. We searched PubMed, Embase, APA PsycINFO, and Web of Science Core Collection (on 10 December 2020) for references on conveying AD biomarker results to individuals without dementia. Our query combined variations on the terms Alzheimer’s disease, disclosure, or diagnosis, preclinical or prodromal, and biomarkers. Two reviewers independently screened the resulting 6860 titles and abstracts for eligibility and examined 162 full-text records for relevance. We included theoretical articles in English, on communicating amyloid and/or tau results to individuals with mild cognitive impairment, subjective cognitive decline, or normal cognition. MAXQDA-software was used for inductive data analysis. Results We included 27 publications. From these, we extracted 26 unique considerations, which we grouped according to their primary relevance to a clinical, personal, or societal context. Clinical considerations included (lack of) validity, utility, and disclosure protocols. Personal considerations covered psychological and behavioral implications, as well as the right to (not) know. Finally, societal considerations comprised the risk of misconception, stigmatization, and discrimination. Overall, views were heterogeneous and often contradictory, with emphasis on harmful effects. Conclusions We found 26 diverse and opposing considerations, related to a clinical, personal, or societal context, which are relevant to diagnosing AD before dementia. The theoretical literature tended to focus on adverse impact and rely on common morality, while the motivation for and implications of biomarker testing are deeply personal. Our findings provide a starting point for clinicians to discuss biomarker-based diagnosis with their patients, which will become even more relevant in light of the conditional approval of a first disease-modifying drug for AD.

using biomarkers. The National Institute on Aging and Alzheimer's Association research framework operationalized AD as a biological construct characterized by evidence of amyloid plaques, tau tangles, and neurodegeneration, irrespective of clinical expression [4]. This implies that AD can be diagnosed before dementia, in individuals with mild cognitive impairment, subjective cognitive decline, or normal cognition. This development has sparked a heated debate. Should a specialist in a memory clinic tell individuals without dementia that they have AD? This may lead to distress [5] as a precise prognosis cannot be given and there is no curative therapy (yet). Alternatively, can physicians withhold information on an underlying disease from patients, just because they do not fulfill clinical dementia criteria? While perhaps avoiding anxiety, this would deprive patients of the opportunity to adopt a risk-reducing lifestyle, prepare for the future, or participate in dementiaprevention trials [6].
The numbers of persons living with preclinical AD are large [7] and many wish to learn their biomarker results [8]. A first estimation suggests the prevalence of AD may be three times higher when based on a biological rather than a clinical definition of the disease, illustrating the potential magnitude of consequences [9]. With the conditional approval of a first disease-modifying therapy [10], this discussion is more relevant than ever.
We aim to provide an overview of ethical, psychosocial, and societal considerations regarding the disclosure of AD pathology before dementia.

Methods
A systematic literature search was conducted and reported according to PRISMA guidelines [11]. Our broad query combined synonyms and spelling variations on the terms "Alzheimer's" AND "disclos*" OR "diagnos*" AND "predementia" AND "biomarkers, " using controlled standardized keywords as well as free text terms. We searched PubMed, Embase, APA PsycINFO, and Web of Science Core Collection for references published before 10 December 2020 and scanned reference lists of identified articles.
All articles in English presenting theoretical data, i.e., ethical concerns, psychosocial consequences, and societal implications of disclosing amyloid and/or tau results to individuals in AT(N) stages 1-3 [4] were eligible (provided the full text was available), except (sections of ) books, editorials, commentaries, and conference proceedings. Publications on later stages and other types of dementia or neurodegenerative diseases were excluded, as well as those primarily focused on trial design or genetic risk.
Two authors independently screened all titles and abstracts. Articles marked as potentially relevant were assessed for eligibility based on full text. In case of discrepancy, arguments for inclusion and exclusion were discussed while re-examining the contents and criteria. In each case, consensus was reached, without having to consult a third author.
We performed inductive content analysis [12], using MAXQDA-software. First, all sections addressing ethical, psychosocial, and societal considerations regarding the disclosure of AD pathology before dementia were identified. Next, the data were processed in an iterative and incremental manner to highlight all aspects pertinent. These were further grouped and aggregated in a hierarchy of categories. This process was repeated and revised until the contents were precisely described and fully covered, by a structure of considerations, with underlying arguments and overarching contexts. An additional classification was made according to the key ethical principles of medical ethics: beneficence, non-maleficence, justice, and autonomy [13].

Results
Our initial search yielded 6860 records. Two reviewers independently screened all titles and abstracts for eligibility and examined 162 full-text records for relevance. After applying selection criteria (Fig. 1), we included 27 articles.
From these, 26 unique considerations were extracted (Table 1), along with supporting arguments, and further categorized according to their primary relevance to a clinical, personal, or societal context. The final coding tree corresponds to the structure of Table 1.
The literature referred to the development of standardized processes and materials for disclosing biomarker levels in prevention trials [17,30,32,37,38], but reported "a complete lack of studies in a clinical setting" [17]. In addition, it was emphasized that the required skills cannot be assumed, so medical professionals would profit from training in risk communication [14,16,18,20,22,25,28,37,38].

Positive and negative psychological impact
Several publications observed the absence and even presence of AD lesions might offer relief, solace, or an explanation of symptoms [17-19, 22-24, 27, 32, 36].

Medicalization
Expanding the criteria for AD raised concerns of tipping the scales from under-to overdiagnosis [14,20,23,28,32,35,37]. Paradoxically, normalization was reasoned to result in marginalization, but also argued to increase the urgency to develop disease-modifying therapies [14].

Advance research
The primary consideration behind the new criteria is to prevent individuals with AD from developing dementia, as early interventions are hypothesized to have better chances of success [14-16, 18, 20, 22, 23, 27-35, 37, 38, 40].

Discussion
We found 26 considerations relevant to disclosing a diagnosis of AD to individuals without dementia. These concerns, constraints, and implications relate to clinical, personal, and societal contexts. Many constitute direct opposites, such as certainty versus uncertainty, reflecting the heated debate among stakeholders. This duality is concordant with findings from a recent study on patients' views regarding early AD diagnosis, reporting not only great variety between individuals but also profound ambivalence within individuals [41]. For example, while a diagnosis can provide certainty on what is going on, it can also bring uncertainty on what to expect. Thus, it may not have to be either one way or the other, as both sides can be true to some extent, and perspectives may change over time. This illustrates the ardent need of empirical evidence and clinical recommendations on a biomarker diagnosis of AD. Since market access has been granted to a first disease-modifying therapy [10], the urgency is even greater, as practitioners, patients, and society are presented with novel opportunities and challenges. Particularly with respect to clinical validity, the comparison of statements was hampered by a disparity of definitions. In the absence of a gold standard, authors evaluated the accuracy of the biomarker framework [4] according to various views on the true state of AD. Findings were based on different criteria of clinical symptoms, pathological findings, and/or biological changes. While all models have value, they are not interchangeable. Moreover, studies suggest the scientific dissensus on nosology and the shifting meaning of AD create confusion [42][43][44][45]. This emphasizes the need for a common concept and language of AD [46].
An underlying and fundamentally contested conundrum is whether individuals with normal cognition, but abnormal biomarkers are ill. Based on research criteria, they have AD but judging by clinical standards they are not sick [21, 27, 30-32, 38, 47]. Two of the included papers evaluate the conceptual validity according to theories of health and disease [26,34]. The authors reasoned that the signature of amyloid and tau does not represent Fig. 2 Visual overview of considerations. Visual overview of 26 considerations extracted from the included literature, categorized based on the clinical, personal, or societal context they relate to and the four basic principles of biomedical ethics: beneficence (doing good), non-maleficence (avoiding harm), justice (ensuring fair distribution of resources in accordance with the law), and autonomy (allowing free, informed, and deliberate decisions). Contested issues, e.g., (in) actionability, are ranked under beneficence as well as non-maleficence to reflect the theoretical debate and their subjective nature. Societal considerations are interrelated, e.g., sharing test results can lead to support but also stigma and discrimination. The visual overview highlights the tension between clinicians' responsibility to weigh the benefits and risks and prevent unnecessary suffering, versus individuals' right to self-determination a singular disease, nor a statistical deviation from normal aging in older people. They concluded that people without symptoms should not be diagnosed as "patients-inwaiting, " but considered persons at-risk [34]. Yet this is not about screening unsuspecting populations. Neither is the phase before dementia entirely without symptoms; individuals present at memory clinics because they experience symptoms in their daily lives, albeit subtle or mild [48,49]. They wish to learn what is wrong, and they have a right to know. In the field of oncology, it is common to diagnose patients with cancer (in situ), regardless of signs or complaints. The same goes for conditions like hypertension and diabetes mellitus [50,51]. An apparent difference is the lack of disease-modifying interventions for AD. Some ethicists apply a "pragmatic view" to AD, stating that without preventive medication early detecting may do more harm than good [34]. This view might change with the recent conditional approval of a first disease-modifying treatment by the FDA. Overall, the identified literature tended to concentrate on putative adverse implications. Notably, repeatedly mentioned worries about conforming to stereotypes or nocebo reactions were substantiated by evidence from a single study on disclosure of genetic risk [52]. Although inherited susceptibility is beyond the scope of our review, extensive research on the impact of revealing an increased probability [53][54][55][56][57][58][59][60] or absolute certainty [61][62][63] of developing dementia has demonstrated that catastrophic outcomes are rare, knowledge of the test results does not affect cognition, and participants also perceive benefits. So far, evidence on disclosing biomarker information is limited, but the few available studies suggest it is safe and actionable [64][65][66][67][68][69]. However, stigmatization and discrimination are concerns that need further scrutiny [70][71][72]. More importantly, it should be noted these findings are based on a selection of individuals, willing to participate and learn their disposition to develop dementia. There is a lack of racial, ethnical, cultural, social, economic, and environmental diversity in study populations [73]. More empirical research is required, evaluating both harms and benefits, taking perspectives of individuals from all groups into account.
The key principles of medical ethics, i.e., beneficence, non-maleficence, justice, and autonomy, were frequently invoked to decide whether a predementia diagnosis of AD is justified. However, applying the "four principle approach" may unduly simplify a complicated matter [74]. The framework relies on the notion of a common morality, while the interest, motivation, and implications of biomarker testing are inherently deeply personal [75]. Yet patients' perspectives and circumstances are underrepresented in the theoretical discourse. Rather than risking paternalism by imposing the moral right to know or not know on all, we need a tailored approach in clinical settings to respect the values of each individual. Future research should illuminate which personal factors influence people's preferences for medical information, as well as the psychological and social implications of disclosing test results. It is pivotal to engage and educate all stakeholders to enable informed (and shared) decision-making and empower individuals in choosing what is best for them. This becomes especially relevant in light of the development of low-cost blood tests [76,77], advances in risk-reducing lifestyle programs [3,[78][79][80][81], and progress on disease-modifying therapies [82][83][84][85].

Strengths and limitations
Our systematic review provides an in-depth overview of considerations regarding a diagnosis of AD before dementia. Strengths are our broad query to include publications from various disciplines (including medical, ethical, psychological, social, and legal), strict adherence to PRISMA guidelines, and use of state-of-the art methodology to inductively analyze the literature. Among the potential limitations is the restriction to articles in English presenting theoretical data. A next step is an inventory of empirical evidence in the clinical, personal, and societal contexts to compare expectations to experiences and identify gaps in knowledge. Immediate requirements include devising educational materials for the general public, protocols for clinical practice, supportive services for patients, and legislation to protect their rights [86]. The identified considerations offer helpful starting points to prepare for a future with precision medicine and prevention of AD.

Conclusions
Diagnosing AD in individuals without dementia involves diverse and often opposing considerations, related to a clinical, personal, or societal context. The theoretical literature tended to focus on adverse impact and rely on the notion of a common morality while the motivation for, and implications of, biomarker testing are deeply personal. Our findings provide a starting point for memory clinic specialists, such as neurologists, geriatricians, and psychiatrists, to discuss a biomarker-based diagnosis with their patients, to enable shared and informed decision-making, which will become even more relevant in light of the conditional approval of a first disease-modifying drug for AD.